Description
Product details
VOLANE SOURCE 450 is a pharmaceutical tablet containing Valganciclovir at a dosage strength of 450 mg. It is a potent antiviral medication primarily designed to treat and prevent certain viral infections caused by cytomegalovirus (CMV), especially in immunocompromised patients such as those undergoing organ transplants or living with HIV/AIDS. Manufactured adhering to strict quality standards under the tablet IP (Indian Pharmacopoeia), VOLANE SOURCE 450 ensures consistent efficacy and safety for patients requiring antiviral therapy. Composition and Pharmacological Profile Each film-coated tablet of VOLANE SOURCE 450 contains 450 mg of Valganciclovir as the active ingredient. Valganciclovir is a prodrug of ganciclovir, meaning it is converted in the body into ganciclovir, which is the active antiviral agent. Its mechanism involves inhibiting viral DNA synthesis by competing with deoxyguanosine triphosphate for incorporation into viral DNA, thereby suppressing the replication of CMV and related herpes viruses. Primary Uses of VOLANE SOURCE 450 Treatment of CMV Retinitis: CMV retinitis is a serious viral eye infection common in patients with weakened immune systems, such as AIDS patients. It leads to inflammation and possible vision loss if left untreated. VOLANE SOURCE 450 is a frontline therapy used to halt the progression of this infection. Prevention of CMV Disease in Transplant Patients: Solid organ transplant recipients and bone marrow transplant patients are at high risk of CMV infection due to immunosuppressive drugs. Prophylactic use of VOLANE SOURCE 450 helps in preventing CMV disease in these vulnerable groups. Treatment of CMV Infection: Apart from retinitis, CMV can cause systemic infections affecting multiple organs, including lungs, digestive tract, and nervous system. VOLANE SOURCE 450 is used for managing such infections effectively. Part of Combination Therapy: It may also be prescribed alongside other antiviral agents as part of combination treatment protocols tailored to complex viral infections, enhancing viral suppression. Key Benefits of Using VOLANE SOURCE 450 High Oral Bioavailability: Being a prodrug, Valganciclovir is well absorbed orally and converted efficiently to ganciclovir in the body, enabling effective antiviral levels. Wide Spectrum of Action: Targets multiple herpesviruses with high specificity, primarily cytomegalovirus, reducing viral load and infection severity. Reduced Risk of CMV Disease Post-Transplant: By preventing CMV infection in transplant recipients, VOLANE SOURCE 450 significantly lowers the risk of post-transplant complications related to viral disease. Convenient Oral Dosage: Unlike intravenous ganciclovir, VOLANE SOURCE 450 allows for easier home administration, improving patient compliance and quality of life. Effective Against Resistant Strains: Used in recurrent and resistant CMV infections, especially where other therapies fail. Protects Vision: In CMV retinitis patients, prompt use of VOLANE SOURCE 450 can preserve vision and prevent blindness due to viral damage. Recommended Dosage and Administration The dosing of VOLANE SOURCE 450 depends on the condition being treated, kidney function, and patient immune status. It is typically prescribed by healthcare professionals following careful medical assessment. For CMV retinitis treatment, the initial dose is usually higher and then tapered down for maintenance. For CMV prophylaxis post-transplant, a standard dose is taken once or twice daily for several months. It is advised to swallow tablets whole with food to enhance absorption. Regular monitoring of blood counts and kidney function is essential during therapy since the drug can impact bone marrow and renal function. Potential Side Effects of VOLANE SOURCE 450 Like any potent antiviral medication, VOLANE SOURCE 450 can cause side effects. Awareness and timely reporting to a healthcare provider are important to manage these effects safely. Common side effects include: Gastrointestinal symptoms: Nausea, vomiting, diarrhea, and abdominal pain. Bone marrow suppression: Leading to anemia, neutropenia (low neutrophils), or thrombocytopenia (low platelets), which increase infection risks and bruising. Headache and fatigue: Mild to moderate headache and tiredness may occur. Fever and infections: Due to immune suppression, secondary infections may arise. Electrolyte imbalance: Occasionally, abnormalities in blood calcium or potassium levels. Rare hypersensitivity reactions: Skin rash, itching, or swelling which require immediate medical attention. Precautions and Contraindications Patients with severe renal impairment require dose adjustments or alternative therapies to avoid toxicity. Pregnant or breastfeeding women should avoid this drug due to potential harm to the fetus or infant. Regular blood tests are necessary to monitor for hematologic or renal side effects. Use caution in patients with pre-existing neutropenia or anemia. Conclusion VOLANE SOURCE 450 (Valganciclovir Tablet IP 450 mg) represents a reliable and efficacious antiviral therapy specifically targeting cytomegalovirus infections. Its role in treatment and prevention of CMV-related diseases, especially among immunocompromised patients, makes it invaluable in clinical practice. Its oral formulation allows for easy administration and effective drug delivery, improving patient adherence and outcomes. While the risk of side effects exists, careful monitoring and adherence to prescribed dosages minimize complications. Overall, VOLANE SOURCE 450 offers a potent solution against serious viral infections, helping preserve health, prevent complications, and improve quality of life for vulnerable patient populations.
